The impact of platelet membrane autoantibodies on high-dose dexamethasone therapy in patients with idiopathic thrombocytopenic purpura.
- Author:
Rui WANG
1
;
Ping QIN
;
Xue-bin JI
;
Ming HOU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Aged, 80 and over; Autoantibodies; blood; Dexamethasone; administration & dosage; therapeutic use; Female; Humans; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; immunology; Platelet Glycoprotein GPIb-IX Complex; immunology; Purpura, Thrombocytopenic, Idiopathic; drug therapy; immunology; Treatment Outcome; Young Adult
- From: Chinese Journal of Hematology 2009;30(9):619-621
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the impact of platelet membrane glycoprotein (GP)-specific autoantibodies on high-dose dexamethasone therapy in patients with idiopathic thrombocytopenic purpura (ITP).
METHODSModified direct monoclonal antibody immobilization of platelet antigen assay (MAIPA) was used to detect platelet GPIIb/IIIa and/or GPI b specific autoantibodies. All patients received oral dexamethasone 40 mg/d for 4 days.
RESULTSThe response rate of high-dose dexamethasone in GPIIb/IIIa and/or GPIb specific autoantibody-negative patients was significantly different from that of antibody-positive patients (P<0.05). The response rate of GPIIb/IIIa specific autoantibody-positive patients was lower than that of antibody-negative patients (P<0.05). GPIb specific autoantibody had no significant impact on the efficacy of high-dose dexamethasone (P>0.05).
CONCLUSIONPlatelet membrane GPIIb/IIIa-specific autoantibody can be a potential negative indicator for ITP patients'response to high-dose oral dexamethasone.
